HBe antigen-negative phenotype has been characterized, in which one TATA box-like motif of the precore/core promoter had degenerated: most frequently by both A -~ T and G -~ A mutations at positions 1762 and 1764, respectively. The clinical significance of this mutant is as yet unknown. In our present study, the T 1762 A TM mutant was sought in sera from HBV-infeeted blood donors and chronic liver disease patients by directly sequencing a PCR-amplified region of HBV DNA. Also, because the A TM mutation generates a Sau3AI cleavage site (GG__TC GATC), we digested the PCR products with Sau3AI to see if cleavage would occur at this specific site. Our results mostly corroborated the earlier report but we found a higher-than-predicted frequency of HBe antigenpositive blood donors positive for the mutant (22 %). The titres of HBe antigen in these mutant-positive sera were slightly decreased compared to the titres in wildtype HBV infection. In addition, these blood donors had relatively high (though within the normal range) serum alanine aminotransferase (ALT) levels, suggesting that the T 176~ A TM mutation could be used as a sensitive laboratory marker for insidious hepatitis in these otherwise 'asymptomatic' carriers. The Sau3AI assay, which is much more convenient than sequencing, was shown to be useful for the detection of the T 176~ A TM mutant in an extensive number of clinical samples.
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The progression from HBe antigenaemia to anti-HBe antibody seroconversion is a typical event during the natural course of persistent infection with hepatitis B virus (HBV). Also typical is the 'genoconversion' of HBV from HBe-positive to HBe-negative phenotype over time (Okamoto et al., 1990) . These two events are closely interlinked in that the anti-HBe antigen (HBeAg) response in infected hosts acts as an immune pressure for HBV mutants with HBeAg-negative phenotype to be selected and replace the wild-type HBV. One classical well-documented set of HBeAg-negative HBV mutants are of the 'precore-defective' type (Brunetto et al., 1989; Carman et al., 1989) , in which the normal HBeAg precursor protein is not produced, owing to nonsense mutation and/or frameshift mutation in the precore region of HBV DNA (Okamoto et al., 1990) . A new set of HBeAg-negative HBV mutants was reported recently (Okamoto et al., 1994) . They are of a 'promoter-* Author for correspondence. Fax +81 3 3764 8992. defective' type in which abolition of HBeAg expression was presumed to be because of a loss of normal architecture in the promoter for the HBeAg precursor protein mRNA (precore/core mRNA).
In our present study, we investigated the mutations in the precore/core promoter region by sequence analyses. We also developed a convenient method for the detection of the most frequent pattern of precore/core promoter mutations (T1762A TM) using Sau3AI digestion and this enabled us to examine an extensive number of clinical samples in order to investigate the clinical implications of this new type of HBV mutant. Our results partly disagreed with the previous report.
Sera or plasma samples were obtained from 96 hepatitis B surface antigen (HBsAg)-positive blood donors (58 HBeAg-positive and 38 HBeAg-negative) and 113 chronic liver disease patients (53 HBeAg-positive and 60 HBeAg-negative). HBsAg status was determined by haemagglutination assay, and HBeAg and anti-HBe antibody were detected by ELISA. Titration of HBeAg (Wang et al., 1990) ; DR1 and DR2, direct repeats 1 and 2. (b) Agarose gel electrophoresis of the PCR products after Sau3AI digestion. Lanes 1 and 7, samples in which the T t762 A T M mutant was clearly demonstrated by direct sequencing.
Lanes 2, 3 and 6, wild-type genome by sequencing. Lanes 4 and 5, samples suggested by sequencing to contain both wild-type and the mutant genome.
was done by reverse-passive haemagglutination assay (R-PHA) using a commercially available kit (Institute of Immunology, Tokyo), and the results were expressed as the highest twofold dilution that gave a positive result. Samples were analysed for the nucleotide sequence of the X/precore/core region of HBV DNA. As shown in Fig. 1 (a), this region (nt 1653-1959, according to the numbering system used in Okamoto et al., 1988) covered the 3' part of X gene (nt 1374-1835), the entire precore (nt 1814-1900), and the 5' part of core gene (nt 1901-2449) . Several regulatory elements, such as the liver-specific enhancer II element (Wang et al., 1990) , precore/core/pregenome promoter (Yuh et al., 1992) and pregenome encapsidation signal (Junker-Niepmann et al., 1990) , are also involved in this region. D N A was extracted from 50 ~tl of each serum by a method described previously (Okamoto et al., 1990) , and dissolved with 50 lal of 10 mM Tris-HC1 pH 8"0/1 mM EDTA. Five p.l of the extracted D N A was mixed with 45 lal of a PCR reaction mixture containing 400 nM of the primers #eP 1-1 nt 1955-1974) , and subjected to 35 cycles of 94 °C for 1 min/55 °C for 1.5 min/72 °C for 2 min. Nested P C R was done using the primers #eP 2-1 (5 nt 1940-1959) in 30 cycles of 94 °C for 1 rain/55 °C for 1 min/72 °C for 1.5 rain. The P C R products were purified with Microcon 100 (Amicon), subjected to a direct sequencing reaction using a commercially available kit (PRISM Ready Reaction Dye Terminator Cycle Sequencing Kit; Applied Biosystems) with the primer #eP 3-1 (5' GAGG-CATACTTCAAAGACTG 3': sense, nt 1698-1717), and electrophoresed on a 373A DNA Sequencer (Applied Biosystems).
(5' G C A T G G A G A C C A C C G T G A A C 3': sense, nt 1606-1625) and #eP 1-2 (5' G G A A A G A -A G T C A G A A G G C A A 3': antisense,

' C A T A A G A G G A C T C T T G G A C T Y: sense, nt 1653-1672) and #eP 2-2 (5' G G C A A A A -A A G A G A G T A A C T C 3': antisense,
A 10 pl aliquot of the nested PCR products with a molecular size of 307 bp was mixed with 10 pl of buffer containing 1 U of Sau3AI (Takara) and incubated at 37 °C for 60 min. Reaction products were then loaded on an agarose gel (4% NuSieve 3:1) and electrophoresed together with molecular size markers to see if cleavage had occurred at the intended site. Expected sizes for the two bands to be generated from the mutant HBV DNA by the Sau3AI digestion were 197 bp and 110 bp, as shown in Fig. 1 (b) .
Samples from 29 HBeAg-positive blood donors, 24 anti-HBeAg-positive blood donors, and 23 chronic liver disease patients were analysed for the X/precore/core sequence of HBV DNA by direct sequencing and also for the digestibility of the amplified DNA with Sau3AI (results are depicted in Fig. 2) . Among the mutations scattered over the sequenced region, remarkable mutations were observed in or near the TArA-box-like motif in the precore/core promoter (TTAAA, nt 1758-1762) and at the 3' end of precore region (nt 1896 and nt 1899). Of the 40 samples in which the TATA-box-like motif had somehow degenerated, 33 (83%) had the pattern of the AT TM and GA TM mutations and all of these were positive for the Sau3AI digestion assay. Two samples from HBeAg-positive blood donors (P030 and P167 in Fig. 2 ) seemed to have a mixture between wildtype HBV and T 1762 A 1764 mutant HBV by direct sequencing and this possibility was further supported by the positive results with the Sau3AI assay even though the digestibility was weak (Fig. 1 b) . In one sample from a patient (CL20 in Fig. 2) , the direct sequencing indicated wild-type but the Sau3A1 assay suggested the coexistence of a trace amount of the T 1762 ATM mutant (Fig. lb) . Table 1 compares the frequencies in our samples of the two types of HBeAg-negative phenotype-related mutants: ' promoter-defective' and 'precore-defective'. The frequency of the promoter-defective mutant was roughly comparable between HBeAg-positive groups and HBeAg-negative groups, but the frequency of the precore-defective mutants showed a remarkable difference between the two categories. Obviously the precore-defective mutation is more strongly associated with HBeAg-negative phenotype than the promoterdefective mutation seems to be. By contrast, the frequency of the promoter-defective mutant showed a striking difference between blood donors and patients, 3 (60%) J * Upper limit of the normal range is 35 Karmen U/1. t The difference between the two groups (indicated by braces) is statistically significant 0f 2 = 7.33; P < 0-01). whereas no such difference was seen for precore-defective mutants. Table 2 correlates the promoter-defective mutant with serum alanine aminotransferase (ALT) levels in blood donors positive for HBeAg. The higher the ALT levels, even within the normal range, the higher the frequency of the mutant. The HBeAg titres were relatively lower in sera from the mutant-positive blood donors, compared with those in the mutant-negative blood donors: the difference was statistically significant with P < 0.01 by Welch's t test (Fig. 3) .
In conclusion, our results agreed with the previous report (Okamoto et al., 1994) in most aspects: (i) T 1762 A TM mutations were the most prevalent of the mutations observed in the precore/core promoter region of HBV DNA; (ii) these 'promoter-defective' mutations occurred independently from those found in the T-terminal region of precore (' precore-defective' mutations); and (iii) most of the chronic liver disease patients examined had the promoter-defective mutant. However, there was a single noteworthy disagreement between the present and previous studies. In the previous study (Okamoto et al., 1994) , the promoter-defective mutants were detected in only 1 (7%) of 14 HBeAg-positive asymptomatic carriers, compared to 15 (58%) of 26 anti-HBeAgpositive asymptomatic carriers, leading to the conclusion by the authors that the promoter mutants are of HBeAgnegative phenotype. Our results throw this conclusion into question.
In our present study, contrary to the previous report, the precore/core promoter mutant (T TM A TM) was detected with similar frequency in HBeAg-positive subjects and in HBeAg-negative subjects in each of the four groups studied: blood donors (22% and 29%, respectively), chronic hepatitis (88% and 66%, respectively), liver cirrhosis (88 % and 89 %, respectively), and hepatocellular carcinoma patients (100 % and 94 %, respectively). These results apparently refute the speculation of Okamoto et al. (1994) that mutations in the core promoter might abort the transcription of pre-C mRNA. Considering the relatively low titres of HBeAg in sera from the mutant-infected blood donors in our study, we propose that the precore/core promoter mutations might have resulted in slightly lower rates of transcription rather than a total supression of the precore/core mRNA. Even in the previous report, the authors found at least three patients who had the promoter mutations in 100 % of HBV clones examined but were still positive for HBeAg. It is, therefore, more appropriate to categorize the phenotype of this mutant as' e-suppressed' rather than as 'e-negative'. The description 'e-negative phenotype' should be reserved for another type of mutants: precore-defective mutants which cannot produce HBeAg.
Our results suggest rather that the precore/core promoter mutant is relevant to disease expression in infected hosts. There were significantly fewer individuals 1
• -0 I I . Titres of HBeAg antigen in the sera from blood donors with and without the precore/core promoter mutant of HBV. Black and white circles are for samples with and without the T 17e2 A 1764 mutant, respectively. Grey circles represent samples that had evidence for mixture of wild-type and the mutant genome sequence. The difference in the HBeAg antigen titres between the two groups is statistically significant (mean and SD of the titres from each group are indicated).
infected with the mutant in asymptomatic blood donors than in chronic liver disease patients: 24/96 (25%) compared to 93/123 (76%) ( P < 0.001; Fisher exact test). Also the frequency of the mutant correlated with the serum ALT levels in HBeAg-positive blood donors (Table 2) . This correlation between the mutant and pathogenesis could be because the mutations in the precore/core promoter cause down-regulation of the transcription of the precore/core mRNA as described above; however, according to Okamoto et al. (1994) , the mutations do not affect the transcription of the HBV pregenome mRNA. Because HBeAg is translated from the former mRNA and core from the latter mRNA, evolution of the mutant would lead to a destruction of the pre-existing balance between HBeAg in the circulation and core peptides presented by class I HLA molecules on the surface of infected hepatocytes. The HBeAg has a suppressive effect on T cells, and in particular, because most of the primary sequence of HBeAg is shared by core, it is plausible that circulating HBeAg may prevent cytotoxic T lymphocytes (CTLs) from recognizing infected hepatocytes which expose core-derived peptides on their surfaces. Most CTLs responsible for the hepatocyte injury in HBV infection are known to be directed to core-derived peptides (Mondelli et al., 1982; Bertoletti et al., 1991) . The slight downward shift, induced by the evolution of the mutant, of the relative amount of HBeAg compared to that of core thus creates a partial liberation of core-specific CTLs from the long-standing suppression exerted by circulating HBeAg, so a greater number of infected hepatocytes would be recognized by CTLs and eventually undergo apoptosis. In this context, it is noteworthy that detection of the T 1762 A T M mutations can be used as a sensitive laboratory marker for insidious hepatitis in ALT-normal carriers of HBV. For such clinical purposes, the Sau3AI digestion assay described in this study is more practical than direct sequencing of PCR-amplified HBV DNA. In our present study, all cases positive for the T TM A TM mutant by direct sequencing were positive also for the Sau3AI digestion. In addition, we found a partial Sau3AIcleavage pattern in sera with a mixture of HBV DNA of wild-type and the mutant forms.
